Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8175MR)

This product GTTS-WQ8175MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Autoimmune diseases research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8175MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2249MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ6759MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DS-1062
GTTS-WQ1990MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ3847MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BCD-054
GTTS-WQ11489MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ12903MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ8569MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ4607MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-986015
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW